FDA to review Vytorin results

January 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

The agency said it will review Merck and Schering Plough Pharmaceuticals' recent trial once the FDA receives the final study results on the drug, which is a combination of Zetia (ezetimibe) and Zocor (simvastatin) in one tablet.

Merck and Schering Plough last week released data showing that the combination drug failed to slow progression of heart disease better than Zocor, which is less expensive.

The FDA said that study was not designed to detect any difference in risk of having a heart attack or stroke between the two treatments. The agency said an ongoing trial is designed to evaluate the effect of Vytorin versus Zocor on heart disease and stroke.

Merck issued a statement Friday in support of the the controversial clinical trial. "We stand behind Vytorin and Zetia and stand behind our science that has brought these cholesterol-lowering medications to millions of people around the world," Peter S. Kim, president of Merck Research Laboratories, said.

Copyright 2008 by United Press International

Explore further: Study lifts cloud over heart drugs Zetia, Vytorin

Related Stories

Study lifts cloud over heart drugs Zetia, Vytorin

November 17, 2014

A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them—evidence ...

FDA backs Vytorin for kidney disease patients

October 31, 2011

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

Study finds no link between statins and cancer risk

July 25, 2011

(Medical Xpress) -- A new study published in the Journal of the American College of Cardiology reports that, contrary to previous studies, the use of cholesterol reducing statin drugs does not increase the risk of patients ...

Study raises new questions about Merck pill Zetia

November 16, 2009

(AP) -- A new study raises fresh concerns about Zetia and its cousin, Vytorin - drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.